71 related articles for article (PubMed ID: 29716549)
1. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Genomic Analysis of
Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
[TBL] [Abstract][Full Text] [Related]
3. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
4. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
5. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.
Zhang Y; Wang J; Fan Y; Lang F; Fu F; Liu Q
Clin Transl Oncol; 2024 Mar; 26(3):653-663. PubMed ID: 37523078
[TBL] [Abstract][Full Text] [Related]
6. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
[TBL] [Abstract][Full Text] [Related]
7. Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine corpus endometrial carcinoma.
Jiang F; Tao Z; Zhang Y; Xie X; Bao Y; Hu Y; Ding J; Wu C
Cell Signal; 2024 May; 117():111077. PubMed ID: 38311301
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological role of Cyclin A2 in uterine corpus endometrial carcinoma: Integration of tissue microarrays and ScRNA-Seq.
Mo WJ; Liang ZQ; Huang JZ; Huang ZG; Zhi ZF; Chen JH; Chen G; Zeng JJ; Feng ZB
Int J Biol Markers; 2024 Jun; 39(2):168-183. PubMed ID: 38646803
[TBL] [Abstract][Full Text] [Related]
9. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
10. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.
Wu J; Zhou X; Ren J; Zhang Z; Ju H; Diao X; Jiang S; Zhang J
Comput Biol Med; 2023 Sep; 163():107164. PubMed ID: 37329616
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis.
Engevik KA; Engevik MA; Engevik AC
PLoS One; 2023; 18(1):e0280428. PubMed ID: 36662766
[TBL] [Abstract][Full Text] [Related]
13. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
[TBL] [Abstract][Full Text] [Related]
14. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract][Full Text] [Related]
15. TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification.
Miao L; Chen B; Jing L; Zeng T; Chen Y
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38305309
[TBL] [Abstract][Full Text] [Related]
16. Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma.
Lei P; Yu L; Sun X; Hao J; Shi W; Sun H; Guo X; Jia X; Liu T; Zhang DL; Li L; Wang H; Xu C
Med Oncol; 2024 Jan; 41(2):48. PubMed ID: 38177789
[TBL] [Abstract][Full Text] [Related]
17. Deciphering DNA repair gene mutational landscape in uterine corpus endometrial carcinoma patients using next generation sequencing.
Lou J; Chu X; Yang X; Jamil M; Zhu H
Am J Cancer Res; 2024; 14(1):210-226. PubMed ID: 38323278
[TBL] [Abstract][Full Text] [Related]
18. Lyl1-deficiency promotes inflammatory responses and increases mycobacterial burden in response to
Jones SS; Ozturk M; Kieswetter NS; Poswayo SKL; Hazra R; Tamgue O; Parihar SP; Suzuki H; Brombacher F; Guler R
Front Immunol; 2022; 13():948047. PubMed ID: 36119114
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of Copy Number Variation, Nucleotide Mutation, and Transcription Level of PPAR Pathway-Related Genes in Endometrial Cancer.
Tang M; Wang J; Fan L
PPAR Res; 2022; 2022():5572258. PubMed ID: 35069712
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma.
Esplen HP; Yang RK; Kalia A; Tang Z; Tang G; Medeiros LJ; Toruner GA
Life (Basel); 2023 Nov; 13(11):. PubMed ID: 38004332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
